The Food and Drug Administration rejected two proposed new cancer drugs that were developed in China, underscoring a tougher U.S. regulatory stance toward such drugs.
Hong Kong-based Hutchmed Ltd. said Monday the FDA issued a letter to the company declining to approve its application to market a new drug, surufatinib, for the treatment of pancreatic and neuroendocrine tumors in the U.S. The drug is approved for use in China.
To Read the Full Story
This post first appeared on wsj.com
